1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC50 of 69.79 ng/mL.
Protein Function: Delta-like protein 4 (DLL4) is a type I membrane protein belonging to the Delta/Serrate/Lag2 (DSL) family of Notch ligands. Notch signaling is an evolutionarily conserved pathway that controls cell fate and is required in multiple developmental processes including vascular development, hematopoiesis, somatogenesis, myogenesis, and neurogenesis. Dysregulation in the Notch pathway is associated with various human diseases. In mammals, four Notch homologs (Notch 1 to 4) and five ligands (DLL 1, 3 and 4, Jagged 1 and 2) have been identified. Notch ligands are transmembrane proteins with a DSL motif necessary for Notch binding, tandem EGF repeats, a transmembrane region and a short intracellular domain (ICD). Notch ligands are categorized into two subfamilies based on the presence of an extracellular cysteine-rich domain and insertions that interrupt some EGF repeats in the Jagged but not the Delta ligand family. Interactions of Notch receptors with their ligands result in reciprocal regulated intramembrane proteolysis (RIP). RIP is a mechanism for transmembrane signal transduction that involves the sequential processing by a disintegrin metalloprotease (ADAM) and then by presenilin/ gamma secretase, resulting in shedding of the extracellular domains and the generation of the soluble ICD signaling fragments, respectively. The Notch ICD translocates to the nucleus and interacts with transcriptional coactivators, resulting in the transcription of target genes. The ICDs of the Notch ligands have also been shown to translocate to the nucleus where they may have a signaling function. DLL4 is expressed highly and selectively within the arterial endothelium and has been shown to function as a ligand for Notch 1 and Notch 4. Human and mouse DLL4 share 86% amino acid sequence identity.
1. Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC50 of 26.54 ng/mL. 2. Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC50 of 69.79 ng/mL.
55.7-64.8 kDa, under reducing condition; 56.6-68.7 kDa, under non-reducing condition
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, 5% Trehalose, pH7.4
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 0.1 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
在 -20°C 下可保存 1 年。避免冷冻/解冻循环。
图片
Recombinant Human DLL4 Protein (rp181238) - ELISA Immobilized Recombinant Human DLL4 Protein (rp181238) at 1.0 μg/mL can bind Navicixizumab (anti-DLL4) (Ab176598) with the EC
₅₀
of 69.79 ng/mL.
Recombinant Human DLL4 Protein (rp181238) - SDS-PAGE 2 μg/lane of Recombinant Human DLL4 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 55.7-64.8 kDa under reducing conditions and 56.6-68.7 kDa under non-reducing conditions.
Recombinant Human DLL4 Protein (rp181238) - Binding Activity Immobilized Recombinant Human DLL4 Protein (rp181238) at 5.0 μg/mL can bind Recombinant Human Notch-1 Protein (rp183726) with the EC₅₀ of 26.54 ng/mL.
ZJ24F0606469
危险品化学品经营许可证（带存储）